Regeneron/Sanofi Offer Free Praluent Samples To Counter Slow Coverage
This article was originally published in The Pink Sheet Daily
Ten days post the US launch of closely-watched Praluent, Regeneron said it plans to distribute free samples of the drug in response to slow reimbursement decisions.
You may also be interested in...
The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.